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S U M M A R Y
Background: Theworldwide increasing resistance to antibiotics has complicated antimicrobial treatment
of urinary tract infections (UTIs), especially in Latin America. This study aimed to report the present
etiology and antimicrobial susceptibility of UTIs, and the effects of the national guidelines for UTIs
introduced in 2003.
Methods: Urine samples were collected from 304 patients with a clinical suspicion of UTI at the
university hospital and primary health centers of Leo´n, Nicaragua. When bacterial growth was reported,
antimicrobial susceptibility tests for nine frequently used antibiotics were performed.
Results: Ninety-one (29.9%) patients had a positive urine culture. The most frequently isolated
microorganisms were Escherichia coli (n = 44), Serratia spp (n = 11), and Escherichia fergusonii (n = 10).
High resistance rates were observed in E. coli to ampicillin (61.4%), cefalothin (45.5%), trimethoprim–
sulfamethoxazole (38.6%), ciproﬂoxacin (31.8%), and ceftriaxone (20.5%). Amikacin and nitrofurantoin
were the only drugs to which >90% of E. coli were susceptible. E. fergusonii and Serratia spp showed
comparable high resistance patterns. Thirteen strains (29.5%) of E. coli were suspected to produce
extended-spectrum beta-lactamase (ESBL).
Conclusions: Resistance rates in community-acquired UTIs in Nicaragua are increasing. The introduction
of therapeutic guidelines with ceftriaxone recommended for upper UTIs and nitrofurantoin for lower
UTIs, has led to increasing resistance against both antibiotics. The emergence of ESBL-producing E. coli is
worrisome, along with the appearance of Serratia spp in the population.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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A high prevalence of symptomatic urinary tract infections
(UTIs) combined with high resistance rates to ﬂuoroquinolones
and beta-lactam antibiotics is one of the greatest problems in the
health systems of Latin American countries.1–3
In theUSA, epidemiological research estimates an incidence of 8
million cases of UTI per year. Annually, this corresponds to a 10.8%
risk of a UTI for women aged 18 years and over. Consequently,
women have a lifetime risk of almost 50% of suffering a UTI, for
which antimicrobial therapy is needed. In Latin American
countries this problem appears to be even more severe.1–3
Escherichia coli is the most frequently isolated uropathogen in
symptomatic UTIs worldwide. The prevalence of other isolated
uropathogens, such as Staphylococcus saprophyticus, Klebsiella spp,
Proteus mirabilis, Serratia spp, and Enterobacter spp, varies between* Corresponding author. Tel.: +31 338501281.
E-mail address: pha.bours@gmail.com (P.H.A. Bours).
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doi:10.1016/j.ijid.2010.02.2264regions and studies.1–7 In 2003 Matute et al., in the ﬁrst large
national prevalence study concerning patients with a symptomatic
UTI, showed that E. coli (56%), Klebsiella spp, (18%) and Enterobacter
spp (11%) were the most commonly isolated uropathogens in
Nicaragua.
Globally, the clinical management of UTIs has been
hampered by increasing resistance rates to frequently used
antibiotics.5–7 In particular, in Latin American countries
where unregulated prescription of antibiotics is more likely,
the resistance patterns of frequently observed uropathogens
are alarming.1–3 Considering these patterns of high resistance,
well chosen antibiotic prescription and usage will reduce the
disease burden of UTIs and thereby lower its consequences and
costs.8,9
The main objective of this study was to gain an insight into the
present situation regarding the etiology and antimicrobial
susceptibility of uropathogens in Nicaragua. The secondary
objective was to analyze the effects of the implementation of
national guidelines in 2003.1 These national guidelines were
introduced tomanage symptomatic UTIs in primary and secondary
care units in Leo´n.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Study design
The authors conducted a cross-sectional study between August
2007 and September 2008 in which 304 patients attending the
university hospital (Hospital Escuela Oscar Danilo Rosales
Argu¨ello; HEODRA) and the primary health centers (PHC) of Leo´n,
Nicaragua were included.
Symptomatic patients were included if they had at least two of
the following inclusion criteria: dysuria, urgency, frequency, fever,
chills, ﬂank pain, nausea or vomiting, suprapubic sensitivity, use of
a Foley catheter, and fever without apparent focus. Patients who
had used antibiotics within the last 7 days were excluded.
Recruitment of patients was carried out at four PHCs throughout
the urban region of Leo´n and from the gynecology, pediatrics, and
internal medicine wards and the emergency rooms of HEODRA.
UTIswere classiﬁed as complicated or uncomplicated according
to a modiﬁcation of the Infectious Diseases Society of America
(IDSA) guidelines. An uncomplicated form of UTI occurs in women
with a normal renal tract and function, who are not in the
menopause, and who are over 12 years of age. Complicated UTIs
are those in pregnant women, male patients, and patients with an
abnormal renal tract, impaired renal function, impaired host
defenses, or a catheter.4,10,11 Based upon the anatomy of the
urinary tract, infections were classiﬁed as lower (cystitis and
urethritis) or upper (pyelonephritis) UTIs.
2.2. Measurements
All patients with a suspected UTI completed a questionnaire on
clinical symptoms and potential risk factors (e.g., diabetesmellitus,
chronic obstructive pulmonary disease (COPD), chronic renal
insufﬁciency, cancer, congenital abnormalities of the urinary tract,
nephrolithiasis, pregnancy, use of a Foley catheter in the last 3
days, and previous UTI) and demographic data (e.g., age, gender,Table 1
Patient characteristics (N=304)
No UTI (n=213) UTI (n=91)
Age, mean (SD) years 20.81 (22.14) 31.81 (29.88)
Age groups, years
<12 117 (54.9) 35 (38.5)
13–50 63 (29.6) 23 (25.3)
>51 30 (14.1) 30 (33.0)
Females 139 (65.3) 69 (75.8)
Hospitalization >48 h 15 (7.0) 8 (8.8)
Location of recruitment
Wards 70 (32.9) 40 (44.0)
Emergency room 106 (49.8) 37 (40.7)
Primary health centers (PHCs) 37 (17.4) 14 (15.4)
Underlying diseases
COPD 7 (3.3) 0 (0)
Renal failure 8 (3.8) 5 (5.5)
Liver cirrhosis 1 (0.5) 4 (4.4)
Diabetes mellitus 14 (6.6) 12 (13.2)
Insulin dependent 2 (0.9) 2 (2.2)
Predisposing factors
Previous UTI 50 (23.5) 27 (29.7)
Catheter 4 (1.9) 12 (13.2)
Pregnant 15 (7.0) 5 (5.5)
Renal stones 4 (1.9) 5 (5.5)
Malformation urinary tract 0 (0) 0 (0)
Prostatic hypertrophy 1 (0.5) 1 (1.1)
Pelvic inﬂammatory disease 3 (1.4) 4 (4.4)
Results are n (%) unless otherwise stated.
UTI, urinary tract infection; SD, standard deviation; COPD, chronic obstructive
pulmonary disease.and area of residence). Additionally, a physical examination was
performed.
All included patients provided amidstream urine sample which
was cultivated at 36 8C for 18–24 h on blood andMacConkey agars.
When bacterial growth of a uropathogen occurred, disk diffusion
tests were performed using the Kirby–Bauer method and the
Clinical and Laboratory Standards Institute (CLSI) criteria.12,13
Signiﬁcant bacterial infection was deﬁned as the growth of 105
colony forming units (CFU)/ml of a single species cultured from
urine 12. Resistance rates to the following antibiotics were
examined: ampicillin, amoxicillin–clavulanate, cefalothin, cipro-
ﬂoxacin, ceftriaxone, gentamicin, trimethoprim–sulfamethoxazole
(TMP–SMX), nitrofurantoin, and amikacin. Resistance tests for
uropathogens other than Enterobacteriaceae were performed
according to CLSI guidelines 13. Non-susceptibility to the third-
generation cephalosporin ceftriaxone was used as an indicator of
extended-spectrum beta-lactamase (ESBL) production 13.
2.3. Statistical analysis
Differences between groups were tested using the Chi-square
test (or Fisher’s exact test when expected frequencies were too
low), with the assumed level of statistical signiﬁcance at a p-value
of <0.05. Data analysis was performed with SPSS version 15.0 for
Windows (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Study population
In total we acquired valid data for 304 study subjects (Table 1).
Ninety-one patients (29.9%) had a positive urine culture. The
majority of the positive samples (75.8%) were collected from
female patients. Sixteen percent of the patients with a demon-
strated UTI had signs and symptoms of pyelonephritis.
The most frequently isolated microorganisms for uncomplicat-
ed and complicated UTI were successively E. coli (n = 44; 48.8%),
Serratia spp (n = 11; 12.1%), and Escherichia fergusonii (n = 10;
11.0%) (Table 2).
Seventy-ﬁve (80.2%) patients with a positive culture were
classiﬁed as having a complicated UTI.10 Of those with positive
urine cultures, only eight (8.8%) patients were hospitalized more
than 48 h before urine sampling. The following pathogens were
cultured from these eight patients: four E. coli, two Cedecea davisae,
one Acinetobacter spp, and one Enterobacter spp.
3.2. Antimicrobial resistance
E. coli (n = 44) showed high resistance rates against ampicillin
(61.4%), amoxicillin–clavulanate (18.6%), ceftriaxone (20.5%),
gentamicin (25.0%), TMP–SMX (38.6%), ciproﬂoxacin (31.8%),
and cefalothin (45.5%). The only drugs against E. coli to whichTable 2
Uropathogens
Pathogens No. of samples (%)
Escherichia coli 44 (48.4)
Serratia spp 11 (12.1)
Escherichia fergusonii 10 (11.0)
Enterobacter spp 6 (6.6)
Cedecea davisae 4 (4.4)
Klebsiella spp 3 (3.3)
Staphylococcus aureus 3 (3.3)
Kluyvera spp 3 (3.3)
Proteus mirabilis 2 (2.2)
Other pathogens 5 (5.5)
Total 91 (100)
Table 3
Antibiotic resistance
% Susceptible 2008 % Resistant 2008 % Resistant 2003 Difference (p-value)b
Escherichia coli (n=44) (n=44) (n=35)
Ampicillina 31.8 61.4 74.0 0.34
Amoxicillin–clavulanatea 69.8 18.6 34.0 0.12
Ceftriaxone 72.7 20.5 0 0.04
Gentamicin 72.7 25.0 11.0 0.16
Trimethoprim–sulfamethoxazolea 59.1 38.6 63.0 0.04
Nitrofurantoina 93.0 7.0 0 0.25
Ciproﬂoxacina 68.2 31.8 30.0 1.0
Cefalothin 45.5 45.5 58.0 0.37
Amikacin 95.3 2.3 0 1.0
Escherichia fergusonii (n=10) (n=10) (n=0)
Ampicillina 10.0 90.0 – –
Amoxicillin–clavulanatea 90.0 0 – –
Ceftriaxone 90.0 0 – –
Gentamicin 50.0 40.0 – –
Trimethoprim–sulfamethoxazolea 40.0 50.0 – –
Nitrofurantoina 100 0 – –
Ciproﬂoxacina 90.0 10.0 – –
Cefalothin 80.0 20.0 – –
Amikacin 87.5 0 – –
Serratia spp (n=11) (n=11) (n=0)
Ampicillina 0 90.9 – –
Amoxicillin–clavulanatea 63.3 9.1 – –
Ceftriaxone 81.8 18.2 – –
Gentamicin 90.9 9.1 – –
Trimethoprim–sulfamethoxazolea 72.7 27.3 – –
Nitrofurantoina 81.8 18.2 – –
Ciproﬂoxacina 72.7 27.3 – –
Cefalothin 27.3 63.6 – –
Amikacin 100 0 – –
Enterobacter spp (n=6) (n=6) (n=7)
Ampicillina 0 100 100 1.0
Amoxicillin–clavulanatea 50.0 33.3 86.6 0.103
Ceftriaxone 66.7 33.3 29.0 1.0
Gentamicin 66.7 33.3 29.0 1.0
Trimethoprim–sulfamethoxazolea 66.7 33.3 29.0 1.0
Nitrofurantoina 83.8 0
Ciproﬂoxacina 50.0 50.0 0 0.070
Cefalothin 40.0 60.0 86.0 0.559
Amikacin 66.7 16.7
Resistance rates were determined according to Clinical and Laboratory Standards Institute guidelines.
a Orally administered antibiotics.
b Chi-square test or Fisher’s exact test.
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(93.0%) and amikacin (95.3%). E. fergusonii (n = 10) showed
relatively high susceptibility rates (Table 3). For Serratia spp
(n = 11), high resistance rates against ampicillin (90.9%), TMP–SMX
(27.3%) and ciproﬂoxacin (27.3%) were observed. Serratia sppwere
susceptible to amikacin and gentamicin (>90%) and to nitrofur-
antoin and ceftriaxone (>80%). Enterobacter spp (n = 6) were only
susceptible to nitrofurantoin (83.8%) and had high resistance to
beta-lactam agents as well as ciproﬂoxacin (Table 3).
Resistance rates between pathogens causing uncomplicated
and complicated UTIs were not signiﬁcantly different. Inclusion or
exclusion of the >48 h hospitalized patients did not reveal
signiﬁcant differences between overall resistance rates.
3.3. Effects of guideline implementation
For ﬁve years, in accordance with the national guidelines,
nitrofurantoin has been the recommended drug for uncomplicated
lower UTIs. In the present study a non-signiﬁcant increase in
resistance to this drug was seen for E. coli (0% vs. 7% p = 0.25).
Reduced usage of beta-lactam antibiotics over the last ﬁve years
has resulted in a decline in resistance to ampicillin (61.4% vs.
74.0%; p = 0.34) and ampicillin–clavulanate (18.6% vs. 34.0%;
p = 0.12). Resistance to TMP–SMX has declined signiﬁcantly
(38.6% vs. 63%; p = 0.04). Due to the use of ceftriaxone as thepreferred drug for upper UTIs, as recommended in the guidelines, a
signiﬁcant increase in resistance has been seen in E. coli since 2003
(20.5% vs. 0%; p = 0.04).
3.4. Extended-spectrum beta-lactamases
Thirteen (29.5%) strains of E. coli were suspected of ESBL
production. Resistance rates in this group were signiﬁcantly
higher to ampicillin (84.6% vs. 51.6%; p = 0.050), amoxicillin–
clavulanate (46.2%vs. 6.5%; p = 0.005), cefalothin (84.6% vs. 29.0%;
p = 0.001), ceftriaxone (69.2% vs. 0%; p = 0.000), and ciproﬂoxacin
(61.5% vs. 19.4%; p = 0.012) compared to pathogens that did not
produce ESBL 13.
4. Discussion
This study reports the recent etiology of UTIs and antimicrobial
susceptibility of uropathogens in Leo´n, a medium-sized Latin
American city. The differences in outcome between this study and
the study performed in 2003 provide an insight into the
development of resistance patterns following the implementation
of therapeutic guidelines in a country with overall high resistance
rates.
With the aim of including as many patients with community-
acquired UTIs as possible, some changes were made between the
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prevalence study was performed not only in the secondary
healthcare setting, but also in the primary healthcare
setting. Furthermore, meropenem was replaced by amikacin to
introduce another important antibiotic class (aminoglycosides). In
daily practice the use of this drug is preferred for economic
reasons.
4.1. Uropathogens
In our study population, themost frequently isolated pathogens
were E. coli, Serratia spp, and E. fergusonii. In the investigation of
2003 the latter two pathogenswere absent in the study population.
Serratia spp are known to be important causes of nosocomial
UTIs throughout the world.14,15 Because this study represents the
community-acquired UTIs in Leo´n, Nicaragua, the high prevalence
of Serratia spp came as a surprise. In our study population, no
signiﬁcant differences in patient characteristics and resistance
rates were seen in those with Serratia spp strains compared to non-
Serratia spp strains. However, recent studies have shown a low
response of Serratia spp to frequently used antibiotics, indicating
the potential danger of this pathogen.14–16
E. fergusonii showed relatively low resistance rates compared to
non-E. fergusonii pathogens. However, the development of resis-
tance in E. fergusonii is unpredictable due to the low incidence of
this pathogen worldwide, and to its recent appearance in the
population of Nicaragua.17,18
4.2. Extended-spectrum beta-lactamases
Worldwide and especially in Latin America, the emerging
problem of ESBL-producing pathogens is worrisome. Various
investigators have shown a high prevalence of ESBL pathogens in
Latin America, varying from 1.7% to 20.8% in E. coli.2,3,16,19 This
study supports the previously described high prevalence of ESBL-
producing pathogens by reporting 29.5% of the E. coli strains as
suspected for ESBL. Unfortunately, ESBL screening was only based
on non-susceptibility to a third-generation cephalosporin, al-
though susceptibility to this antibiotic has been described for
ESBL-positive uropathogens.13 ESBL conﬁrmatory tests were not
performed. Nevertheless, the prevalence of ESBL-producing
pathogens in community-acquired UTIs is high in our study
compared to other investigations in Latin America.
4.3. Antimicrobial resistance
The international literature has alerted physicians all over the
world to the problem of increasing resistance rates in uropatho-
gens.1–7 High resistance rates against TMP–SMX are seen as a
worldwide problem because this antibiotic is used as a ﬁrst-line
treatment in uncomplicated UTIs. Studies from Latin America have
not only shown high resistance rates to TMP–SMX, but also to
other common and inexpensive orally administered agents, such
as ampicillin and ciproﬂoxacin.1–3 In 2003, Matute et al. showed
that resistance rates in Nicaragua were alarmingly high. The
resistance of uropathogens in Nicaragua in 2008 is of even greater
concern. High resistance rates were present against TMP–SMX, but
also against beta-lactam antibiotics, aminoglycoside antibiotics,
and ﬂuoroquinolones. Therefore, the risk of clinical failure when
using these agents increases and thereby usage becomes clinically
unacceptable.20,21
This study has evaluated the effects of the therapeutic
guidelines implemented in Nicaragua in 2003. Implementation
led to a decrease in resistance against ampicillin and TMP–SMX
without clinical importance. Resistance against amoxicillin–
clavulanate decreased to 18.6%, which can therefore become analternative to nitrofurantoin in the treatment of uncomplicated
UTIs in the future. Then again, in the current situation susceptibil-
ity rates were too low for the effective use of amoxicillin–
clavulanate (susceptibility 69.8%). A limitation of this study is that
the authors did not determine how often the guidelines were
followed over the past ﬁve years.
Resistance against nitrofurantoin, which is the ﬁrst choice
antibiotic in uncomplicated lower UTIs in Nicaragua, increased
from 0 to 7%. Despite the fact that this increase demonstrates that
frequent use of a certain antibiotic for a long period of time will
elevate the resistance, this resistance is clinically acceptable
(susceptibility >90%).4,20 Usage of ceftriaxone, until now the
preferred antibiotic for upper UTIs, is nowadays no longer clinically
acceptable (susceptibility 72.2%). Therefore, the switch to another
therapeutic regime is inevitable.
4.4. Conclusions and recommendations
The situation we are facing in Nicaragua is challenging because
of the increased overall resistance of uropathogens, resulting in a
growing lack of therapeutic options for UTIs. The introduction of
therapeutic guidelines, with ceftriaxone recommended in upper
UTIs and nitrofurantoin in lower UTIs, has led to increasing
resistance against both antibiotics. The emergence of ESBL-
producing E. coli is worrisome, along with the appearance of
Serratia spp in the population.
Physicians facing comparable high resistance rates should
avoid the risk of losing an effective antibiotic cure. Therefore, the
choice of a sensible antibiotic regime is essential. In cases of
uncomplicated lower UTIs, the authors recommend a 5-day course
of nitrofurantoin as the empirical treatment of ﬁrst choice, despite
increasing resistance rates after implementation of the national
guidelines.22,23 In cases of complicated lower UTIs, experience has
shown that the risk of clinical failure is higher.4,24,25 Therefore, we
recommend antibiogram assessment while starting with nitrofur-
antoin therapy in these cases. Special attention should be given to
patients in this group who develop symptoms of tissue inﬁltration,
i.e. signs of an upper UTI. For these patients, nitrofurantoin should
not be a therapeutic option because of the poor tissue penetration
of this drug.4,26,27
In cases of upper UTI, therapeutic options are running out.
Regarding resistance rates, parenteral use of amikacin in an
inpatient setting should be the ﬁrst choice therapy in all cases of
upper UTI, complicated and uncomplicated. When an antibiogram
has been assessed, the change to a susceptible oral antibiotic can be
made.
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